BIRMINGHAM, AL, UNITED STATES, January 8, 2026 / EINPresswire.com / — Rampart, a Birmingham, Alabama–based medical device ...
The CCTS supports translational science pilot projects that align with the CCTS mission of accelerating the translation of research into improvements for human health and healthcare delivery. Projects ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
In our clinical fellowship program, you will learn the breadth of common and rare infectious diseases in a variety of inpatient and ambulatory settings from nationally recognized leaders in infectious ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
HOUSTON--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect ...
The Baylor College of Medicine Board of Trustees, Academic Council and Faculty Senate have approved a new Clinical Psychology Program, which will award a Doctor of Philosophy degree through the School ...
PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune ...
Lexeo Therapeutics, Inc. announced a private placement financing that aims to raise approximately $80 million through the sale of over 20 million shares of its common stock and pre-funded warrants.
Management anticipates top line data from the EXPLORE-OSA trial in the near future and continues to focus on pre-NDA preparations for lorundrostat, with a scheduled meeting with the FDA in Q4 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback